Acharekar Maitri V, Guerrero Saldivia Sara E, Unnikrishnan Sumedha, Chavarria Yeny Y, Akindele Adebisi O, Jalkh Ana P, Eastmond Aziza K, Shetty Chaitra, Rizvi Syed Muhammad Hannan A, Sharaf Joudi, Williams Kerry-Ann D, Tariq Maha, Balani Prachi
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Ophthalmology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2022 Aug 4;14(8):e27691. doi: 10.7759/cureus.27691. eCollection 2022 Aug.
Gastrointestinal motility disorders have been thought to occur due to an imbalance in the interaction of the gut-brain axis, which is regulated by serotonin. This recent discovery can be exploited to find newer therapeutic agents such as selective serotonin reuptake inhibitors for functional gastrointestinal disorders. PubMed, PubMed Central (PMC), and Medline databases were used to obtain the data. Meta-analyses, systematic reviews, randomized control trials, and reviews were included and analyzed in the data. Of the 19240 studies, 23 were extracted, and after appropriate quality assessment, they were utilized in this systematic review. They included two meta-analyses, four systematic reviews, two randomized control trials, and 15 review articles. The systematic review focuses on the efficacy of selective serotonin reuptake inhibitors (SSRIs) as compared to other treatment modalities for disorders of gut-brain interaction. It explores various studies analyzing SSRIs for their mechanism of action, their desirable effects for treating irritable bowel syndrome, and their tolerability in patients. SSRIs are effective and safe in treating overall symptoms of gastrointestinal motility disorders, particularly constipation-predominant disorders. They seem to have a better side effect profile than other drugs. This should encourage physicians to prescribe SSRIs early on in the disease.
胃肠动力障碍被认为是由于肠道-脑轴相互作用失衡所致，而这种相互作用由血清素调节。这一最新发现可用于寻找新型治疗药物，如用于功能性胃肠疾病的选择性血清素再摄取抑制剂。利用PubMed、PubMed Central（PMC）和Medline数据库获取数据。纳入并分析了荟萃分析、系统评价、随机对照试验和综述。在19240项研究中，提取了23项，经过适当的质量评估后，将其用于本系统评价。其中包括两项荟萃分析、四项系统评价、两项随机对照试验和15篇综述文章。该系统评价聚焦于选择性血清素再摄取抑制剂（SSRI）与其他治疗肠道-脑相互作用障碍的治疗方式相比的疗效。它探讨了各项分析SSRI作用机制、治疗肠易激综合征的预期效果及其在患者中的耐受性的研究。SSRI在治疗胃肠动力障碍的总体症状方面，尤其是以便秘为主的疾病方面，是有效且安全的。它们似乎比其他药物具有更好的副作用表现。这应促使医生在疾病早期就开具SSRI处方。
